| Document |
Document Title |
|
WO/2023/064493A1 |
This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.
|
|
WO/2023/064225A1 |
Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or diso...
|
|
WO/2023/064343A1 |
Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical comp...
|
|
WO/2023/061999A1 |
The present invention discloses a distinct mode of action of a nickel catalyst to forge C-0 bonds to unlock the mild utilization of N2O as O-atom transfer reagent in the synthesis of complex phenols from the corresponding aryl halides.
|
|
WO/2023/057548A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
|
|
WO/2023/038093A1 |
Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the Î...
|
|
WO/2023/026222A1 |
The present invention relates to the development of therapeutic compound for the treatment of brain psychiatric diseases. Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt or suitable...
|
|
WO/2023/007188A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or pol...
|
|
WO/2023/288197A1 |
The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
|
|
WO/2023/281455A1 |
Present invention relates to development of compound of formula (I) for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt ...
|
|
WO/2022/271801A1 |
The present disclosure provides methods of producing a compound of structural formula (I): (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/271557A1 |
Provided herein are processes for the preparation of (S)-2-(2,6- dioxopipelidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-l
-yl) methyl) benzyl)amino)isoindoline-l, 3-dione, or a salt, solvate, hydrate, enantiomer, mixture of enantiome...
|
|
WO/2022/272062A1 |
Described herein are compounds that are EP2 antagonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditi...
|
|
WO/2022/266162A1 |
Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
|
|
WO/2022/242581A1 |
Provided herein are compounds of Formula Ia and Ib, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (R...
|
|
WO/2022/236118A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of compounds that modulate a target in the brain including sphingosine- 1 -phosphate receptor (S1P1), lysophosphatidic acid receptor 1 (LPA1), G-protein coupled receptor 120 ...
|
|
WO/2022/236133A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restrict...
|
|
WO/2022/221774A1 |
The invention features compounds and pharmaceutical compositions useful for treating 5-HT2 responsive conditions. Also provided are methods of using the compounds or compositions of the invention for treating 5-HT2 responsive conditions ...
|
|
WO/2022/219246A1 |
The present invention relates to a compound of formula (I) wherein A, Z, L, R1, R2, R3, R4, R5 and R33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors o...
|
|
WO/2022/199865A1 |
The present invention relates to a novel crystalline compound of Siponimod Hemifumarate, to processes and to intermediates for its preparation, to pharmaceutical compositions containing it and to the use in therapy.
|
|
WO/2022/204288A1 |
The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. ...
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/174083A1 |
The invention features compounds which modulate FGF activity, e.g., by enhancing the binding between FGF-2 and its receptors, e.g., FGF-R1. Also featured is a pharmaceutical composition containing one or more of the compounds, a method o...
|
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/160466A1 |
A 2-cyanoacrylate compound and use thereof for preventing and treating fungal diseases of crops, belonging to the field of fungicides. The 2-cyanoacrylate compound has good fungicidal activity, particularly has good fungicidal activity a...
|
|
WO/2022/156827A1 |
The present invention relates to an allicin derivative, having the structure as shown in formula I, and a preparation method and use therefor, wherein R1 and R2 are respectively an alkyl group having 1 to 4 carbons, a cycloalkyl group, a...
|
|
WO/2022/155037A1 |
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1‑R8, X, Y, Z, X', Y'...
|
|
WO/2022/152705A1 |
Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and formula (II) are as defined in the description. Medicaments.
|
|
WO/2022/133040A1 |
Provided are kinases inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some em...
|
|
WO/2022/127863A1 |
Provided are a crystal form 2, a crystal form 8, a crystal form 10, and a crystal form 16 of a hemifumarate salt of formula (I), preparation methods therefor, and uses thereof. The crystal form 2, crystal form 8, crystal form 10, and cry...
|
|
WO/2022/127655A1 |
The present invention provides an NLRP3 inflammasome inhibitor and the use thereof in the preparation of a drug for preventing or treating NLRP3 inflammasome-related diseases. The NLRP3 inflammasome inhibitor of the present invention can...
|
|
WO/2022/107724A1 |
The present invention provides: a novel azetidinone derivative having excellent herbicidal activity, or a salt thereof; an herbicide containing the same as an active ingredient; and a production intermediate. Provided are: an azetidinone...
|
|
WO/2022/109043A1 |
Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose...
|
|
WO/2022/087008A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2022/084298A1 |
The present application relates to compounds of formula (I), or pharmaceutically acceptable salts thereof: wherein R1 and R2 represent hydrogen or deuterium; R3 represents hydrogen, -COOH or -OH; R3' and R3" represent hydrogen, methyl, m...
|
|
WO/2022/084280A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a -COOH group or a -OH group; R3' and R3" rep...
|
|
WO/2022/063784A1 |
Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods fo...
|
|
WO/2022/064007A1 |
The presented invention relates to solid forms of Siponimod adipic acid salt and cocrystal.
|
|
WO/2022/067114A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2022/059684A1 |
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof.　Specifically provided is a vitamin D derivative represented by formula (1), or a p...
|
|
WO/2022/056045A1 |
The present disclosure provides SPNS2 inhibitor compounds according to Formula (IA) and Formula (I), and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmace...
|
|
WO/2022/040172A1 |
The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
|
|
WO/2022/029598A1 |
The invention discloses a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof that binds tightly to a hydrophobic binding pocket of Mdm2, preventing binding of Mdm2 to the tumour suppressor p53 and increasing p53 ...
|
|
WO/2022/022612A1 |
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/020222A1 |
The present invention is directed to compositions containing a fatty acid amide hydrolase inhibitor and methods of use thereof for treatment of trauma-related psychiatric disorders in a patient in need thereof, particularly those that ex...
|
|
WO/2022/013408A2 |
The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceuti...
|
|
WO/2021/262483A1 |
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present inven...
|
|
WO/2021/262541A1 |
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present d...
|
|
WO/2021/251337A1 |
CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compo...
|
